Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question:

Would you rather buy VIVUS (Nasdaq: VVUS) or buy Arena (NASDAQ: ARNA)?

Healthcare analysts David Williamson and Michael Douglass continue their game of "would you rather" by discussing two competing obesity drug makers struggling with lackluster sales. Watch and find out which stock David chooses and his arguments for it.